Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Avalo Therapeutics has completed enrollment of approximately 250 adults in its Phase 2 LOTUS trial evaluating AVTX-009 for moderate to severe hidradenitis suppurativa. - The global trial compares subcutaneous bi-weekly and monthly dosing regimens of AVTX-009 against placebo, with topline data expected in mid-2026. - Analysts project potential stock upside of over 200% if the drug achieves HiSCR75 response rates of 25-30%, with the company highlighting superior IL-1β inhibition as a competitive advantage. - Multiple investment firms have initiated bullish coverage, with target prices ranging from $25 to $50, reflecting confidence in the drug's therapeutic potential.
- MoonLake Immunotherapeutics received positive FDA feedback confirming the company can establish substantial evidence of effectiveness for sonelokimab in hidradenitis suppurativa using existing VELA-1, VELA-2, and MIRA trial data without conducting additional clinical studies. - The FDA specifically advised including MIRA trial results in the BLA submission and recommended submitting VELA-2 data to inform the safety profile, regardless of its utility in establishing effectiveness. - Based on the Type B meeting outcomes, MoonLake will proceed with BLA submission for sonelokimab in hidradenitis suppurativa in the second half of 2026. - The company demonstrated strong clinical performance across over 1,000 patients, with sonelokimab achieving 43% HiSCR75 response in MIRA and meeting all primary endpoints in VELA-1 with statistical significance.
- MoonLake's sonelokimab demonstrated clinically meaningful and statistically significant benefit in the Phase 2 LEDA trial for palmoplantar pustulosis, achieving a 64% mean reduction in disease severity at week 16. - The company reported positive interim data from multiple clinical trials, including 46% of adolescent patients achieving HiSCR75 response in the VELA-TEEN trial for hidradenitis suppurativa. - MoonLake confirmed a Type B meeting with the FDA scheduled for December 15, 2025, to discuss the adequacy of clinical evidence for a Biologics License Application submission planned for Q3/Q4 2026. - The company maintains strong financial position with $380.5 million in cash and securities, providing runway into the second half of 2027 to support multiple Phase 3 trials across inflammatory diseases.
- MoonLake's sonelokimab achieved 46% HiSCR75 response rate in adolescent hidradenitis suppurativa patients during the Phase III VELA-TEEN trial at 16 weeks. - The drug previously underperformed against UCB's Bimzelx in adult HS trials, achieving only 34.8% and 35.9% HiSCR75 rates compared to Bimzelx's 64% at 96 weeks. - Sonelokimab also demonstrated positive Phase II results in palmoplantar pustulosis with 64% reduction in PPPASI scores and 39% of patients achieving 75% or greater improvement. - MoonLake plans FDA discussions in December 2025 for potential BLA submission and will advance sonelokimab to Phase III PPP trials in Q3 2026.
- Moonlake Immunotherapeutics' experimental drug sonelokimab delivered mixed results in two late-stage hidradenitis suppurativa trials, with one study meeting statistical significance but falling short of investor expectations. - The drug achieved a 35% response rate versus 18% for placebo in one trial, while failing to meet its primary endpoint in the second study due to higher than expected placebo response. - Wall Street analysts expressed skepticism about the drug's approval path and commercial potential, describing the results as "disappointing" and "undifferentiated" compared to existing treatments. - Moonlake's stock price crashed from approximately $62 to less than $10 following the results announcement, representing more than 80% decline in market value.
- MoonLake Immunotherapeutics reported week 16 results from its Phase 3 VELA program, with sonelokimab achieving statistical significance in VELA-1 but missing the primary endpoint in VELA-2 due to higher-than-expected placebo response rates. - The combined VELA program demonstrated clinically meaningful improvements across all primary and secondary endpoints, with 35% of patients achieving HiSCR75 response compared to 22% on placebo using treatment policy analysis. - Sonelokimab maintained a favorable safety profile with no new safety signals detected, and the company plans to discuss regulatory pathways for hidradenitis suppurativa with authorities while continuing development across multiple inflammatory conditions.
- DelveInsight's 2025 pipeline analysis reveals over 20 companies are actively developing 20+ novel therapies for ankylosing spondylitis treatment across various clinical phases. - UCB's BIMZELX demonstrated long-term inflammation control in three-year Phase 3 data, while becoming the first dual IL-17A/IL-17F inhibitor approved in Canada for ankylosing spondylitis. - Multiple promising candidates including sonelokimab, NEU-111, and secukinumab are advancing through clinical trials, targeting different pathways to address unmet medical needs. - The pipeline encompasses diverse therapeutic approaches including monoclonal antibodies, small molecules, and nanobodies administered through oral, subcutaneous, and intravenous routes.
- MoonLake Immunotherapeutics is advancing Sonelokimab, a novel Nanobody® targeting IL-17A/A, A/F, and F/F dimers, through multiple Phase 3 trials for immunologic diseases. - The Phase 3 VELA trials for hidradenitis suppurativa launched in May 2025 with results expected in mid-2025, while the Phase 3 IZAR program for psoriatic arthritis begins in Q4 2024. - The company is expanding into new indications including palmoplantar pustulosis and axial spondyloarthritis, with Q2 2025 results scheduled for August 7. - Positive Phase 2 results in psoriatic arthritis support the advancement to Phase 3 trials, with primary endpoint readout expected in the first half of 2026.
- Merck has entered into a definitive agreement to acquire Verona Pharma for $10 billion, adding the first-in-class COPD treatment Ohtuvayre to its respiratory portfolio. - Ohtuvayre represents the first novel inhaled mechanism for COPD maintenance treatment in over 20 years, combining bronchodilator and anti-inflammatory effects in a single molecule. - The acquisition addresses Merck's need to diversify revenue streams ahead of Keytruda's patent expiry in 2028, with the transaction expected to close in Q4 2025. - Ohtuvayre generated over 96% of Verona's $76 million first-quarter revenue and is also being evaluated for non-cystic fibrosis bronchiectasis treatment.
- Merck has held acquisition talks with Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, according to Financial Times reports citing three people familiar with the matter. - The pharmaceutical giant submitted a nonbinding offer earlier this year which was initially rejected, though discussions could potentially be revived as Merck seeks to rebuild its pipeline. - The acquisition interest comes as Merck faces the looming patent expiration of its blockbuster cancer drug Keytruda beginning in 2028, creating urgency to diversify its revenue streams. - MoonLake's shares surged 19% in extended trading following the acquisition reports, while the biotech's position ahead of late-stage clinical data strengthens its negotiating position.
